An Observational Follow-up Study to Investigate the Duration of Treatment Effect With Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain (PARA_OA_006)

Paradigm Biopharmaceuticals Ltd · ClinicalTrials.gov

The durability question the OA program was built to answer: time from initial response in PARA_OA_002 to loss of OMERACT-OARSI response, followed to 34 weeks. Registry checked 2026-08-15 — completed 24 December 2024, record last updated July 2025, no results posted and no publication indexed.

Population

133 participants carried forward from the PARA_OA_002 knee-OA trial

Intervention

Observational follow-up of the parent trial's PPS arm

Comparator

Observational follow-up of the parent trial's placebo arm

Limitations

Observational extension of an unblinded-to-the-reader parent trial whose own symptom results remain unpublished; no results posted more than eighteen months after completion, so nothing here can yet be appraised.